Share Email Print

Proceedings Paper

Activity of glycated chitosan and other adjuvants to PDT vaccines
Author(s): Mladen Korbelik; Judit Banáth; Evaldas Čiplys; Zdzislaw Szulc; Alicja Bielawska; Wei R. Chen
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Glycated chitosan (GC), a water soluble galactose-conjugated natural polysaccharide, has proven to be an effective immunoadjuvant for treatment of tumors based on laser thermal therapy. It was also shown to act as adjuvant for tumor therapy with high-intensity ultrasound and in situ photodynamic therapy (PDT). In the present study, GC was examined as potential adjuvant to PDT-generated cancer vaccine. Two other agents, pure calreticulin protein and acid ceramidase inhibitor LCL521, were also tested as prospective adjuvants for use in conjunction with PDT vaccines. Single treatment with GC, included with PDT vaccine cells suspension, improved the therapeutic efficacy when compared to vaccine alone. This attractive prospect of GC application remains to be carefully optimized and mechanistically elucidated. Both calreticulin and LCL521 proved also effective adjuvants when combined with PDT vaccine tumor treatment.

Paper Details

Date Published: 9 March 2015
PDF: 5 pages
Proc. SPIE 9324, Biophotonics and Immune Responses X, 932407 (9 March 2015); doi: 10.1117/12.2077276
Show Author Affiliations
Mladen Korbelik, British Columbia Cancer Agency (Canada)
Judit Banáth, British Columbia Cancer Agency (Canada)
Evaldas Čiplys, Vilnus Univ. Institute of Biotechnology (Lithuania)
Zdzislaw Szulc, Medical Univ. of South Carolina (United States)
Alicja Bielawska, Medical Univ. of South Carolina (United States)
Wei R. Chen, Univ. of Central Oklahoma (United States)

Published in SPIE Proceedings Vol. 9324:
Biophotonics and Immune Responses X
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?